Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Renal Cell: early-phase trial registry
6 of 35 indexed Carcinoma, Renal Cell trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 6 currently recruiting · #435 of 28,707 conditions by registered trial count
Carcinoma, Renal Cell: 35 US clinical trials tracked, 6 recruiting.
Carcinoma, Renal Cell is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 8 of these trials.
Enrollment posture brief
Registry condition carcinoma-renal-cell
OPEN 6 | RECR 17% | LATE 6 | EARLY 27 | RANK #435 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Gliosarcoma (17% recruiting · 35 trials)
Carcinoma, Renal Cell lists 6 open slots (17% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Renal Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Renal Cell is recruiting below its size-band peers.
6 of 35 indexed trials (17.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoma, Renal Cell research.
Merck Sharp & Dohme accounts for 8 of 35 trials (22.9%). 21 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Renal Cell enrolment sits around 75 participants.
Median target enrolment is 75 among the 35 trials that report a genuine target (sentinel values excluded). 18 of those (51.4%) plan for fewer than 100 participants.
-
Carcinoma, Renal Cell research is mostly interventional.
33 interventional and 2 observational studies make up this index (94.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
NCT07227415
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Travera
NCT05461430
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
NCT05287945
Autologous Dendritic Cell Vaccine in Kidney Cancer
Jodi Maranchie
NCT05127824
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
State University of New York at Buffalo
NCT06222593
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Merck Sharp & Dohme
NCT05239728
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Merck Sharp & Dohme
NCT04736706
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme
NCT04195750
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Merck Sharp & Dohme
NCT04586231
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Merck Sharp & Dohme
NCT04626479
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Merck Sharp & Dohme
NCT04626518
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Merck Sharp & Dohme
NCT04489771
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT05544929
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
Duke University
NCT02978118
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
NCT03091192
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
Merck Sharp & Dohme
NCT04846920
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
Columbia University
NCT04028245
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
NCT00083889
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
GlaxoSmithKline
NCT00244764
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01307267
Study To Assess Long Term Safety Of Pazopanib
Novartis Pharmaceuticals
NCT00387205
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
Abbott
NCT00073125
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
GlaxoSmithKline
NCT00256880
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The Methodist Hospital Research Institute
NCT00445042
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
Bayer
NCT00044564
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
Pharmacyclics
NCT00134186
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Cancer Institute (NCI)
NCT00923481
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Agensys
NCT01672775
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
NCT00043368
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Genzyme, a Sanofi Company
NCT00356460
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
NCT00325507
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
NCT00083941
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Duke University
NCT03109015
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
Celgene
NCT00106301
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 14 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Renal Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Renal Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Renal Cell page
35 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Carcinoma, Renal Cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merck Sharp & Dohme sponsors the most Carcinoma, Renal Cell trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Renal Cell condition card totals 35 registered trials; most-linked intervention Belzutifan; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.